Tag archive for ‘Vivus Inc.’
Implications Stemming From FDA Requirement for Extremely Large Cardiovascular Outcomes Study for Orexigen’s Contrave (VVUS, $8.00)
Stock Opinion The FDA has shown great reluctance to approve three anti-obesity agents under development: Orexigen’s ($2.11, OREX) Contrave, Vivus’ ($8.17, VVUS) Qnexa and Arena’s ($1.38, ARNA) Lorques. All three drugs received complete response letters following their NDA submissions and the companies are in the process of addressing the FDA’s concerns before refilling their NDAs. […]
For Yearly-Access Subscribers Only
Teaser excerpts
For Monthly-Access Subscribers Only
Teaser excerpt